Product Information
33139-1-PBS targets KIF18B in IF/ICC, IP, Indirect ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag36663 Product name: Recombinant human KIF18B protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-110 aa of BC136590 Sequence: MAVEDSTLQVVVRVRPPTPRELDSQRRPVVQVVDERVLVFNPEEPDGGFPGLKWGGTHDGPKKKGKDLTFVFDRVFGEAATQQDVFQHTTHSVLDSFLQGYNCSVFAYGA Predict reactive species |
| Full Name | kinesin family member 18B |
| Calculated Molecular Weight | 852 aa, 93 kDa/833 aa, 91 kDa |
| Observed Molecular Weight | 100 kDa |
| GenBank Accession Number | BC136590 |
| Gene Symbol | KIF18B |
| Gene ID (NCBI) | 146909 |
| RRID | AB_3742867 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity Purification |
| UNIPROT ID | Q86Y91 |
| Storage Buffer | PBS only, pH 7.3. |
| Storage Conditions | Store at -80°C. |
Background Information
KIF18B is a key member of the kinesin-8 family, involved in regulating various physiological processes such as microtubule length, spindle assembly, and chromosome alignment. This article briefly introduces the structure and physiological functions of KIF18B, examines its role in malignant tumors, and the associated carcinogenic signaling pathways such as PI3K/AKT, Wnt/β-catenin, and mTOR pathways. Research indicates that the upregulation of KIF18B enhances tumor malignancy and resistance to radiotherapy and chemotherapy. KIF18B could become a new target for anticancer drugs, offering significant potential for the treatment of malignant tumors and reducing chemotherapy resistance (PMID: 39259333).
